Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.07 - $6.95 $17,013 - $110,505
-15,900 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$5.46 - $8.29 $86,814 - $131,811
15,900 New
15,900 $109,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $661M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Worth Venture Partners, LLC Portfolio

Follow Worth Venture Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Worth Venture Partners, LLC with notifications on news.